- A 60-year-old woman with cirrhosis due to chronic hepatitis C (treated with sustained virologic response) presents for follow-up. She reports increasing abdominal girth and ankle swelling despite limiting salt "most days." She denies confusion or GI bleeding. Medications include spironolactone 100 mg daily and furosemide 40 mg daily. Exam shows ascites and 2+ leg edema without asterixis. Labs: Na 129 mEq/L, creatinine 1.0 mg/dL, albumin 2.7 g/dL, INR 1.6, total bilirubin 2.2 mg/dL. Ultrasound 6 months ago shows nodular liver and moderate ascites; no mass. She has not had paracentesis before. What is the next best step in management for this patient?
Answer: Perform diagnostic paracentesis to evaluate new/worsening ascites
This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's increasing abdominal girth and edema despite diuretics suggest worsening ascites, requiring immediate assessment and treatment to prevent complications. The correct choice, performing diagnostic paracentesis to evaluate new/worsening ascites, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, adding amlodipine to improve renal perfusion and natriuresis, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.
- Surveillance ultrasound shows a new 8-mm liver nodule in a cirrhotic liver. What is the next best step?
Answer: Ultrasound in 3 months
At 8 mm, the nodule is below the 1 cm threshold for diagnostic imaging; repeat surveillance ultrasound in 3 months to assess growth. A multiphasic CT or MRI is tempting, but nodules under 1 cm are often not characterized reliably and require short-term follow-up rather than immediate cross-sectional imaging or biopsy.
- A 60-year-old woman with cirrhosis presents with increasing abdominal distension. Paracentesis reveals a serum-ascites albumin gradient (SAAG) of 1.6 g/dL and ascitic total protein 0.9 g/dL. She has no fever and PMN count is 40 cells/mm³. Ultrasound shows cirrhosis and portal hypertension. Which of the following findings is most consistent with portal hypertensive ascites?
Answer: SAAG ≥1.1 g/dL
This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's SAAG of 1.6 g/dL and low ascitic protein suggest portal hypertensive ascites, requiring immediate assessment and treatment to prevent complications. The correct choice, SAAG ≥1.1 g/dL, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, SAAG <1.1 g/dL, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.
- A 67-year-old man with decompensated alcoholic cirrhosis and large-volume ascites presents with fatigue and decreased urine output over three days. His home medications include furosemide 80 mg daily and spironolactone 200 mg daily. On examination, his blood pressure is 92/58 mm Hg and heart rate is 105/min. Laboratory studies show a serum creatinine of 2.1 mg/dL (baseline 1.1 mg/dL) and a BUN of 45 mg/dL. What is the most appropriate initial step in management?
Answer: Hold diuretics and administer intravenous albumin.
This patient presents with acute kidney injury (AKI) in the setting of cirrhosis and aggressive diuresis, suggesting a pre-renal cause from volume depletion. The first step in managing suspected hepatorenal syndrome (HRS) is to rule out other causes of AKI. This involves holding diuretics and providing a volume challenge with intravenous albumin (typically 1 g/kg). If renal function does not improve after this intervention, a diagnosis of HRS-AKI is more likely, and treatment with vasoconstrictors (midodrine, octreotide) would be appropriate. A renal ultrasound is useful to rule out post-renal obstruction but the volume challenge is the more immediate therapeutic and diagnostic step.
- A 64-year-old woman with cryptogenic cirrhosis has refractory ascites, defined as ascites that is unresponsive to a maximal diuretic regimen (furosemide 160 mg/day, spironolactone 400 mg/day) and a sodium-restricted diet. She requires therapeutic large-volume paracentesis every 10-14 days for symptomatic relief. Her MELD-Na score is 18, and she has no history of overt hepatic encephalopathy. What is the most appropriate next step in the long-term management of her ascites?
Answer: Referral for transjugular intrahepatic portosystemic shunt (TIPS) evaluation.
This patient has refractory ascites. The primary treatment options are serial large-volume paracentesis (LVP) or TIPS. Since she is already requiring frequent LVP, TIPS is the definitive next step to consider for long-term control. It decompresses the portal system, reducing ascites formation. In a patient with a reasonable MELD score and no history of encephalopathy, TIPS is an excellent option. Midodrine is for HRS, albumin infusions are not a standard long-term strategy, and indwelling catheters have a very high infection risk.
- A 59-year-old man with alcoholic cirrhosis is found to have moderate ascites during a hospitalization. A diagnostic paracentesis is performed. Ascitic fluid analysis shows a total protein of 0.8 g/dL and a cell count of 150 cells/mm³ with 30% polymorphonuclear leukocytes (PMNs). He has never had an episode of spontaneous bacterial peritonitis (SBP). What is the most appropriate management regarding SBP prophylaxis for this patient upon discharge?
Answer: Initiate long-term prophylaxis with daily ciprofloxacin.
The patient's ascitic fluid PMN count is 45 cells/mm³ (150 * 0.30), which is below the diagnostic threshold for SBP (>250 cells/mm³). However, long-term SBP prophylaxis is indicated in patients with ascites who have a low ascitic fluid protein concentration (<1.5 g/dL) because this indicates a deficit in ascitic fluid opsonic activity, increasing infection risk. This patient's protein is 0.8 g/dL, meeting the criteria for primary prophylaxis. Daily ciprofloxacin or norfloxacin is a standard regimen.
- A 48-year-old man is newly diagnosed with cirrhosis secondary to chronic hepatitis B infection. He is started on tenofovir. His childhood immunization records are unavailable. In addition to the standard influenza and pneumococcal vaccinations, which of the following immunizations is most critical to administer to this patient?
Answer: Hepatitis A vaccine.
Patients with chronic liver disease, particularly cirrhosis, are at high risk for fulminant hepatic failure if they acquire a superimposed acute viral hepatitis. Therefore, all non-immune patients with chronic liver disease should be vaccinated against hepatitis A and hepatitis B. Since this patient already has hepatitis B, ensuring immunity to hepatitis A is critical. The other vaccines are either less critical in this context (HPV, zoster) or potentially contraindicated if decompensated (MMR is a live vaccine).
- A 50-year-old man with alcohol-associated cirrhosis is evaluated after an episode of hematemesis treated endoscopically with band ligation of esophageal varices. He is now stable and preparing for discharge. He continues to have ascites controlled with diuretics. Vitals are stable; hemoglobin is stable. What is the next best step in management to reduce recurrent variceal bleeding risk?
Answer: Start a nonselective beta-blocker and arrange repeat banding sessions
This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's recent variceal bleed treated with banding suggests need for secondary prophylaxis, requiring immediate assessment and treatment to prevent complications. The correct choice, starting a nonselective beta-blocker and arranging repeat banding sessions, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, starting a proton pump inhibitor as sole long-term prophylaxis, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.
- A 63-year-old woman with compensated cirrhosis from NASH tells her physician she has been following a low-protein diet because a previous doctor told her it would 'protect her liver.' She reports fatigue and has noticed significant muscle wasting over the past year. She has no personal history of overt hepatic encephalopathy. What is the most appropriate nutritional advice for this patient?
Answer: Encourage a daily protein intake of 1.2 to 1.5 g/kg of ideal body weight.
When you encounter cirrhosis questions on Step 3, remember that nutritional management has evolved significantly from older practices. The key principle is that protein restriction is only indicated during acute hepatic encephalopathy episodes, not as routine management.
This patient with compensated cirrhosis and muscle wasting needs adequate protein intake. Modern hepatology guidelines recommend 1.2-1.5 g/kg of ideal body weight daily for cirrhotic patients without acute encephalopathy. Her fatigue and muscle wasting are classic signs of protein-energy malnutrition, which is common in cirrhosis and actually worsens outcomes. Answer D provides the evidence-based protein target that will help restore her muscle mass and improve her functional status.
Answer A perpetuates an outdated approach. Prophylactic protein restriction in stable cirrhosis patients increases malnutrition risk without preventing encephalopathy. Answer B suggests "hepatic rest" through liquid diets - this concept isn't supported by current evidence and would worsen her nutritional status. Answer C focuses on weight loss through macronutrient restriction, but this patient needs adequate nutrition to address her muscle wasting, not further dietary restrictions.
The modern understanding is that well-nourished cirrhotic patients tolerate complications better and have improved survival. Protein restriction should only be temporary during acute encephalopathy episodes, then liberalized as tolerated.
Step 3 tip: When you see cirrhosis + nutrition questions, ask yourself if the patient currently has encephalopathy. If not, favor adequate protein intake over restriction - the old "low-protein for liver disease" approach is largely outdated except during acute encephalopathic episodes.
- A 60-year-old woman with compensated cryptogenic cirrhosis (Child-Pugh class A) undergoes a screening esophagogastroduodenoscopy (EGD). The procedure reveals small esophageal varices with no red wale signs. The patient has never had a gastrointestinal bleed. What is the most appropriate management for her varices?
Answer: Repeat endoscopy in 1 to 2 years.
Current guidelines for primary prophylaxis of variceal bleeding recommend that patients with compensated cirrhosis and small varices without high-risk stigmata (e.g., red wale signs) do not require immediate treatment with non-selective beta-blockers or band ligation. The recommended approach is surveillance with a repeat EGD in 1-2 years to monitor for an increase in variceal size, which would then prompt initiation of prophylactic therapy. Beta-blockers are typically reserved for medium/large varices or decompensated cirrhosis.
- A 61-year-old man with cirrhosis is being managed for recurrent overt hepatic encephalopathy. He is adherent to a lactulose regimen that results in two to three soft bowel movements per day. Despite this, he continues to have breakthrough episodes of confusion requiring hospitalization every 2-3 months. What is the most appropriate next step in his outpatient management?
Answer: Add rifaximin to his current lactulose regimen.
This patient is experiencing recurrent overt hepatic encephalopathy (HE) despite standard first-line therapy with lactulose. In such cases, the addition of rifaximin is the recommended second-line therapy. Rifaximin is a non-absorbable antibiotic that reduces ammonia-producing enteric bacteria and has been shown to reduce the risk of HE recurrence. Further increasing lactulose is likely to cause side effects, protein restriction is contraindicated as it worsens sarcopenia, and TIPS would worsen HE.
- A 55-year-old man with hepatitis C-related cirrhosis is being discharged from the hospital following successful endoscopic band ligation for bleeding esophageal varices. During his admission, he received octreotide, ceftriaxone, and proton pump inhibitors. He is now hemodynamically stable and tolerating an oral diet. Which of the following is the most important addition to his discharge medication regimen to prevent rebleeding?
Answer: A non-selective beta-blocker.
For secondary prophylaxis of variceal hemorrhage (i.e., preventing rebleeding after an initial bleed), the standard of care is the combination of endoscopic band ligation and pharmacotherapy with a non-selective beta-blocker (e.g., nadolol or propranolol). This combination is superior to either modality alone. PPIs do not prevent variceal rebleeding. Antibiotic prophylaxis is typically given for 5-7 days during the acute bleed but is not continued long-term for this indication. Diuretics are for ascites management.
- A 54-year-old woman is seen for follow-up three months after receiving a liver transplant for cirrhosis due to NASH. She is maintained on an immunosuppressive regimen of tacrolimus, mycophenolate mofetil, and a low-dose prednisone taper. Her blood pressure is 155/92 mm Hg, and her serum creatinine is 1.8 mg/dL (her baseline before transplant was 0.8 mg/dL). Her liver function tests are normal. What is the most likely cause of her hypertension and renal dysfunction?
Answer: Calcineurin inhibitor-induced nephrotoxicity.
Tacrolimus is a calcineurin inhibitor (CNI) and a cornerstone of most liver transplant immunosuppression regimens. The most common and significant side effects of CNIs are nephrotoxicity and hypertension. The mechanism involves afferent arteriolar vasoconstriction in the kidney. Given the clinical picture of new-onset hypertension and elevated creatinine with normal liver function tests, CNI toxicity is the most likely diagnosis. Rejection and recurrent NASH would primarily affect liver enzymes, and CMV infection would typically present with other systemic symptoms.
- A 72-year-old man with decompensated cirrhosis is found to have a serum sodium of 122 mEq/L on routine laboratory testing. He is asymptomatic, euvolemic on exam, and has stable vital signs. His ascites is well-controlled on his current diuretic regimen. His urine sodium concentration is <10 mEq/L. What is the most appropriate initial management for his hyponatremia?
Answer: Restriction of free water intake to 1.5 liters per day.
This patient has asymptomatic hypervolemic hyponatremia, a common complication of advanced cirrhosis caused by non-osmotic release of antidiuretic hormone (ADH), leading to impaired free water excretion. The cornerstone of initial management is restricting free water intake (typically to 1-1.5 L/day). Hypertonic saline is reserved for severe, symptomatic cases. Discontinuing diuretics could worsen ascites, and vasopressin antagonists (vaptans) are second-line agents due to cost and risk of overly rapid correction.
- A 62-year-old woman with cirrhosis due to nonalcoholic steatohepatitis (NASH) undergoes a routine 6-month surveillance ultrasound. The report describes a new 1.8-cm hyperechoic lesion in the right hepatic lobe. Her alpha-fetoprotein (AFP) level is 12 ng/mL. What is the most appropriate next step in management?
Answer: Obtain a multiphasic contrast-enhanced CT or MRI of the liver.
For a newly detected liver lesion between 1 and 2 cm in a cirrhotic patient, the standard diagnostic algorithm requires further characterization with multiphasic cross-sectional imaging (either a 4-phase CT or dynamic contrast-enhanced MRI). These studies can identify the characteristic vascular features of hepatocellular carcinoma (HCC), such as arterial phase hyperenhancement and venous/delayed phase washout, which can be diagnostic without a biopsy. Repeating the ultrasound is an unacceptable delay, biopsy is reserved for indeterminate lesions on cross-sectional imaging, and TACE is a treatment, not a diagnostic step.
- A 55-year-old man with cirrhosis is admitted with confusion and ascites. He is afebrile and hemodynamically stable. Paracentesis shows PMN 40 cells/mm³. He has not had recent imaging. Exam shows jaundice and asterixis. Which workup step is most appropriate to evaluate for common precipitants of encephalopathy?
Answer: Assess for infection, GI bleeding, constipation, and electrolyte abnormalities
This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's confusion and asterixis suggest encephalopathy with potential precipitants, requiring immediate assessment and treatment to prevent complications. The correct choice, assessing for infection, GI bleeding, constipation, and electrolyte abnormalities, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, ordering liver biopsy urgently to confirm cirrhosis, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.
- A 66-year-old man with cirrhosis and ascites presents with several months of progressive dyspnea on exertion. On examination, his oxygen saturation is 95% while lying flat but decreases to 88% when he sits upright. His lungs are clear to auscultation, and a chest X-ray shows only a small right-sided pleural effusion. An echocardiogram shows normal left and right ventricular function. Which of the following is the most likely cause of his dyspnea?
Answer: Hepatopulmonary syndrome.
The patient's clinical presentation is classic for hepatopulmonary syndrome (HPS). The pathognomonic finding is platypnea-orthodeoxia: dyspnea (platypnea) and hypoxemia (orthodeoxia) that are worse in the upright position and improve with lying down. This occurs due to intrapulmonary vascular dilatations that are most pronounced at the lung bases, leading to increased shunting and V/Q mismatch in the upright posture. Hepatic hydrothorax would cause dyspnea but not the positional desaturation, and portopulmonary hypertension presents with signs of right heart failure.
- A 65-year-old man with alcoholic cirrhosis underwent a TIPS procedure four weeks ago for refractory ascites. His ascites has resolved, but his family brings him to the clinic for worsening confusion and daytime sleepiness. On examination, he is disoriented to time and place and has prominent asterixis. He is taking lactulose twice daily. What is the most likely cause of his neurologic decline?
Answer: Worsening hepatic encephalopathy from portosystemic shunting.
When you encounter a patient with cirrhosis who develops new neurological symptoms after a TIPS procedure, immediately consider hepatic encephalopathy as the primary concern. TIPS (transjugular intrahepatic portosystemic shunt) creates a direct connection between portal and systemic circulation, which can worsen encephalopathy by allowing ammonia and other toxins to bypass hepatic detoxification.
This patient's presentation perfectly fits hepatic encephalopathy: confusion, disorientation, asterixis (flapping tremor), and daytime sleepiness occurring weeks after TIPS placement. The timeline is classic - neurological decline following the procedure that successfully treated his ascites but created increased portosystemic shunting.
Option A (subdural hematoma) would typically present with focal neurological signs, headache, or evidence of trauma, none of which are described. Option B (alcohol-related dementia) progresses gradually over months to years, not acutely over four weeks. Option C (spontaneous bacterial peritonitis) is unlikely since his ascites has resolved, and SBP typically presents with abdominal pain, fever, and systemic signs of infection rather than isolated neurological symptoms.
The correct answer is D because TIPS procedures commonly cause or worsen hepatic encephalopathy in 20-30% of patients by increasing the ammonia load reaching systemic circulation. Despite being on lactulose (which helps reduce ammonia absorption), his encephalopathy has progressed due to the mechanical bypass of liver detoxification.
Remember: New neurological symptoms after TIPS = think hepatic encephalopathy first. This is a well-known complication that can occur despite appropriate medical management with lactulose.
- A 57-year-old woman with compensated cirrhosis (Child-Pugh class A) due to autoimmune hepatitis presents with new-onset right knee pain and swelling consistent with an osteoarthritis flare. Her current medications for her liver disease are well-tolerated. Which of the following analgesic medications should be strictly avoided in this patient?
Answer: Naproxen.
Non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen should be avoided in patients with cirrhosis. NSAIDs inhibit prostaglandin synthesis, which is critical for maintaining renal blood flow in the setting of portal hypertension and splanchnic vasodilation. Their use can precipitate acute kidney injury and hepatorenal syndrome. They also increase the risk of gastrointestinal bleeding. Acetaminophen is safe at reduced doses (≤2 g/day), tramadol can be used cautiously, and topical agents are safe.
- A 60-year-old woman with known cirrhosis due to hepatitis C presents with worsening ascites and mild confusion. She has no fever. Paracentesis shows PMN 260 cells/mm³. She is treated for SBP and improves. To reduce recurrence risk, what is the next best step in management after completing antibiotics?
Answer: Start long-term SBP prophylaxis with oral antibiotic therapy
This question tests the management of chronic liver disease and cirrhosis, focusing on clinical decision-making appropriate for independent practice. Chronic liver disease requires careful monitoring and management of complications such as ascites, hepatic encephalopathy, and variceal bleeding. In this vignette, the patient's history of SBP suggests need for prophylaxis, requiring immediate assessment and treatment to prevent complications. The correct choice, starting long-term SBP prophylaxis with oral antibiotic therapy, reflects the appropriate initial management step, aligning with current guidelines for managing cirrhosis and its complications. A common distractor choice, no prophylaxis is needed if symptoms resolve, fails because it suggests a non-standard treatment, highlighting a common misconception about liver disease management. To aid learning, emphasize the importance of lifestyle modifications and regular monitoring of liver function to manage and prevent progression of cirrhosis. Encourage the practice of applying standardized guidelines to diverse clinical scenarios.
